P. Joy Ho, MBBS

Prof. Joy Ho is Clinical Professor, University of Sydney, and Director of Research, Head of Myeloma Research Unit and Acting Director of Haematology at the Institute of Haematology, Royal Prince Alfred Hospital (RPAH), Australia. After Haematology training she was awarded the Oxford Nuffield Medical Fellowship in 1994 and completed doctoral studies at Oxford University. In 1998 Dr. Ho re-joined RPAH and has been a key member of the Myeloma Research Unit, becoming Head in 2013.

In 2009, she was Visiting Associate Professor at Cornell University. Her research achievements in myeloma include stewardship of national Myeloma trials eg currently Chief Investigator of Australasian Lymphoma and Leukemia Group (ALLG) MM16 trial. She has brought multiple trials on novel myeloma therapies and immunotherapy to her institution and Australia; she was RPAH principal investigator of one of the first chimeric antigen receptor-T cell trials in Australia. She is an integral member of the RPAH Myeloma Laboratory research unit, which she now heads, studying T cell immunopathology. For the International Myeloma Society, in 2005 she was Chair of the Scientific Committee of the International Myeloma Workshop in Sydney. She has served on the IMS Education Committee for many years. She is Deputy Chair of the Medical and Scientific Advisory group of Australian Myeloma Foundation, and member of the International Myeloma Working Group. Previously she served on the ALLG Scientific Committee and chaired the Laboratory Sciences Committee. She was President of Haematology Society of Australia and New Zealand from 2013 to 2015. For American Society of Hematology, she is invited member of the International Members’ Committee since 2016, and Chair of Metrics subcommittee since 2018. In 2017, she was appointed to the Pharmaceutical Benefits Advisory Committee by the Australian Government. Awards received include the Albert Baikie Memorial Medal, Kanematsu Memorial Award and Arnott Fellowship in Cancer Research.